前列腺癌治療市場規模、佔有率和成長分析（按藥物類型、分銷管道和地區）- 產業預測 2025-2032

2023 年攝護腺癌治療市場規模價值 121 億美元，預計將從 2024 年的 130.6 億美元成長到 2032 年的 239.9 億美元，預測期內（2025-2032 年）的複合年成長率為 7.9%。

全球市場格局正在經歷充滿活力且不斷發展的轉變，主要原因是人口老化、意識提高和早期診斷導致男性前列腺癌發病率不斷上升。發病率的快速增加刺激了創新治療方法的發展。然而，高昂的治療費用和潛在的副作用等問題可能會阻礙其更廣泛地應用。關鍵成長要素包括藥物選擇的增加、大量的研發投入、複雜的藥物管道的引入、以及非轉移性去勢抗性和轉移性荷爾蒙非依賴性疾病的荷爾蒙療法的擴展。新興經濟體中尚未開發的商業機會可能會進一步推動這個市場的發展，儘管在恢復時間和需求方面會受到一些限制。個人化治療策略和增強藥物針對性的轉變可能會推動未來的進步並顯著改善患者的治療效果。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

前列腺癌治療市場規模（按藥物類型和複合年成長率） (2025-2032)

• 市場概況
• 用荷爾蒙療法治療前列腺癌
  • 黃體激素釋放激素 (LHRH) 拮抗劑
  • 澤瀉
  • 戈納克斯
  • 黃體激素釋放激素 (LHRH)促效劑
  • 亮丙瑞林
  • Zoladex
  • 艾利加德
  • 十甲哌啶
  • 萬塔斯
  • 其他
  • 抗雄激素
  • 贊迪
  • 卡索得
• 攝護腺癌化療
  • Taxotere
  • 傑夫塔納
• 攝護腺癌免疫治療
  • Provenge
• 標靶治療
  • 佐菲戈
• 其他前列腺癌

前列腺癌治療市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 藥局和藥房
• 網路藥局

前列腺癌治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• GSK Plc（UK）
• Merck KGaA（Germany）
• Viatris Inc.（USA）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Exelixis Inc.（USA）
• IBSA Pharma（IBSA Group）（Switzerland）
• Abbott Laboratories（USA）
• Alvogen Iceland ehf（Iceland）
• Fresenius SE & Co. KGaA（Germany）
• Jerome Stevens Pharmaceuticals Inc.（USA）
• Lannett Co. Inc.（USA）
• Lupin Ltd.（India）
• Mayne Pharma Group Ltd.（Australia）
• Piramal Enterprises Ltd.（India）
• RLC Labs Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）

結論和建議

Prostate Cancer Treatment Market size was valued at USD 12.1 billion in 2023 and is poised to grow from USD 13.06 billion in 2024 to USD 23.99 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

The global prostate cancer treatment market presents a vibrant and evolving landscape, primarily driven by the increasing prevalence of prostate cancer among men due to an aging population, heightened awareness, and early diagnosis. This surge in incidence fosters the development of innovative treatments. However, challenges such as high treatment costs and potential side effects may hinder broader adoption. Key growth factors include the rise in pharmaceutical options, significant R&D investments, the introduction of complex pipeline drugs, and the expansion of hormonal therapies in both non-metastatic castration-resistant and metastatic hormone-naive conditions. Untapped opportunities in developing economies could further propel this market, albeit with some limitations in healing periods and demand. A shift toward personalized treatment strategies and enhanced drug targeting will likely drive future advancements, improving patient outcomes significantly.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Treatment Market Segments Analysis

Global Prostate Cancer Treatment Market is segmented by Drug Type, Distribution Channel and region. Based on Drug Type, the market is segmented into Hormonal Prostate Cancer Therapy, Prostate Cancer Chemotherapy, Prostate Cancer Immunotherapy, Prostate Cancer Targeted Therapy and Others Prostate Cancer. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Prostate Cancer Treatment Market

The Prostate Cancer Treatment market is primarily driven by the rising prevalence of prostate cancer, which is influenced by various factors such as an aging global population and advancements in awareness and diagnostic techniques. As the population ages, it is expected that prostate cancer incidence will rise significantly, particularly since the disease predominantly affects older men. Enhanced awareness and widespread screening initiatives have contributed to the earlier detection of prostate cancer, leading to increased reported cases. These elements highlight the pressing need for effective treatment options and foster the development of innovative therapies within this dynamic market.

Restraints in the Prostate Cancer Treatment Market

The global market for prostate cancer treatment encounters notable obstacles, primarily due to the substantial costs linked to targeted therapies and immunotherapies. While these advanced treatment options have demonstrated significant potential for enhancing patient outcomes, their affordability poses a serious challenge. The expenses associated with therapies like immunosuppressants can be exceedingly high, imposing a considerable financial strain on both patients and healthcare systems. This elevated cost frequently restricts access to these crucial therapies, hindering the ability to provide effective care. A limited number of patients worldwide face the difficult task of managing the financial implications, highlighting the urgent need to address cost-related barriers to ensure wider access to these potentially life-saving treatments.

Market Trends of the Prostate Cancer Treatment Market

The prostate cancer treatment market is increasingly trending towards personalized medicine, highlighting a shift towards tailored therapeutic strategies based on individual genetic and molecular profiles. Advances in genomic testing allow for the identification of specific biomarkers, enabling healthcare providers to select the most effective treatment options while minimizing unnecessary interventions and side effects. Technologies such as the Prostate Health Index and genomic tests like Oncotype DX are at the forefront of this transformation. Furthermore, targeted therapies like olaparib and rucaparib are becoming critical in treating advanced cases by addressing DNA repair pathway alterations, enhancing the overall efficacy of prostate cancer management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Prostate Cancer Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Hormonal Prostate Cancer Therapy
  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
  • Zytiga
  • Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
  • Lupron
  • Zoladex
  • Eligard
  • Decapeptyl
  • Vantas
  • Others
  • Anti-Androgen
  • Xtandi
  • Casodex
• Prostate Cancer Chemotherapy
  • Taxotere
  • Jevtana
• Prostate Cancer Immunotherapy
  • Provenge
• Prostate Cancer Targeted Therapy
  • Xofigo
• Others Prostate Cancer

Global Prostate Cancer Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Prostate Cancer Treatment Market Size & CAGR (2025-2032)

• North America (Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBSA Pharma (IBSA Group) (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvogen Iceland ehf (Iceland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jerome Stevens Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RLC Labs Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations